Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13697613 | 0.98 | HTR6 (0.36) | OPRL1HTR6HRH3SIGMAR1IDH1 | |
| SCHEMBL14494758 | 0.98 | HTR6 (0.36) | OPRL1HTR6HRH3SIGMAR1IDH1 | |
| SCHEMBL21594221 | 0.92 | HTR6 (0.39) | OPRL1HTR6HRH3SIGMAR1KCNH2 | |
| SCHEMBL30683689 | 0.88 | HRH3 (0.40) | HRH3SIGMAR1KCNH2MEN1KMT2A | |
| SCHEMBL10863656 | 0.85 | HRH3 (0.34) | OPRL1HTR6HRH3SIGMAR1KCNH2 | |
| SCHEMBL13697558 | 0.84 | KDM4E (0.33) | IDH1 | |
| SCHEMBL13697514 | 0.84 | KDM4E (0.33) | IDH1 | |
| SCHEMBL13697554 | 0.84 | ACKR3 (0.31) | IDH1 | |
| SCHEMBL14494674 | 0.84 | IDH1 (0.32) | HRH3SIGMAR1IDH1 | |
| SCHEMBL14494672 | 0.82 | SMN1; SMN2 (0.41) | OPRL1HRH3L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | BDKRB1, BDKRB2, VIPR1 | OPRL1 38/4885HTR6 453/4885HRH3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.